Study guide
18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
Key Takeaways Explain This Topic AI
Bhopal (methyl isocyanate), radium dial painters, Minamata (methylmercury), thalidomide, DDT raptor declines, and TGN1412 each illustrate a distinct toxicological failure mode still used on the DABT.
Epidemiological dose-response evaluation requires exposure reconstruction from measured or modeled doses; an ever/never exposure label is not a dose.
NHANES is a repeated, nationally representative cross-sectional biomonitoring survey released in two-year cycles; it describes population trends, not individual diagnosis or community-level causation.
Age, comorbidities, ethnicity as a marker of allele frequency and differential exposure, and polymorphisms such as NAT2, CYP2D6, ALDH2, PON1, and G6PD identify susceptible subgroups.
Incident investigations use chain-of-custody specimen handling and immunoassay screen followed by GC-MS or LC-MS/MS confirmation, plus risk communication that treats uncertainty and outrage as part of the response.
Last updated: September 2026
Once an environmental residue exists, Domain IV of the ABT 2026 Candidate Handbook moves from ecosystems to people . IV.2 asks you to respond to public-health issues, including events of major toxicological significance and emerging risks. IV.4–6 ask you to reconstruct exposure for epidemiology, read population biomonitoring such as the National Health and Nutrition Examination Survey ( NHANES ), and identify susceptible subpopulations . This independent ExamFinch section teaches those tasks as one investigation workflow: history → exposure metric → who is at extra risk → how you sample and talk about it. It is not an official ABT text and it is not a forensic-toxicology board exam; laboratory methods appear here only as tools of a public-health investigation.
Lessons from events of major toxicological significance (IV.2 B)
The handbook names a short list. Learn each event as a mechanism plus a regulatory or practice lesson , not as trivia.
Event Agent / setting What went wrong biologically Practice lesson still tested
Bhopal , December 1984, Union Carbide pesticide plant, India Methyl isocyanate (MIC) released from bulk storage after water entered a tank; MIC is a highly reactive, volatile isocyanate Acute corrosive injury to airways and eyes, pulmonary edema, reactive airways; thousands of acute deaths and hundreds of thousands of injuries (official counts vary) Inventory of a water-reactive intermediate, relief-system design, community warning, and medical surge for a dense urban population
Radium dial painters , 1910s–1920s (U.S. luminous-watch industry) Radium-226 (and related radionuclides) in paint; workers lip-pointed brushes Bone-seeking alpha emitter; jaw osteonecrosis ("radium jaw"), aplastic anemia, later osteosarcoma Occupational hygiene, prohibition of mouth-tipping, and the idea that internal emitters have organ-specific dosimetry
Minamata Bay , Japan (recognized 1956; releases earlier) Methylmercury from acetaldehyde production (mercury catalyst) discharged to the bay; fish and shellfish dietary exposure Adult Hunter-Russell picture: ataxia, dysarthria, concentric visual-field loss, distal sensory loss; congenital Minamata disease from transplacental MeHg Industrial effluent can poison a food web; fetal brain is a sensitive target; fishing bans and dietary advisories are exposure controls
Thalidomide , late 1950s–early 1960s Oral sedative/antiemetic; critical window about days 20–36 of human pregnancy Phocomelia and other malformations; rats were relatively insensitive compared with rabbits and primates Species choice and timing of developmental exposure; the 1962 Kefauver-Harris Amendments strengthened U.S. drug evidence requirements after FDA reviewer Frances Kelsey kept the drug off the U.S. market
DDT and the ecological cascade Persistent organochlorine insecticide; DDE metabolite Avian eggshell thinning via disrupted calcium deposition in the shell gland; raptor and pelican population crashes through biomagnification, not acute bird LC50s in a beaker Population- and community-level endpoints; U.S. cancellation of most uses in 1972 and later raptor recovery
TGN1412 (theralizumab), Northwick Park, London, March 2006 Humanized CD28 superagonist monoclonal antibody; six healthy volunteers dosed nearly together Life-threatening cytokine storm (cytokine release syndrome) within hours; multi-organ failure; all six survived, with lasting injury in some First-in-human starting dose for agonists cannot rest on a large NOAEL safety factor from cynomolgus monkeys when receptor pharmacology differs; MABEL (minimal anticipated biological effect level), sentinel dosing, and cytokine monitoring entered practice
Two pairings are frequent distractors. Bhopal is MIC , not methylmercury. Minamata is MeHg in fish , not an isocyanate cloud. Thalidomide is a developmental window and species-sensitivity story, not an alpha-emitting bone seeker. TGN1412 is immunopharmacology and first-in-human design , not a chronic environmental residue.
Emerging risks: climate, infrastructure, food scarcity, infectious disease (IV.2 C)
The handbook wants a conceptual map, not a climate-model workshop.
Climate. Heat increases volatilization of some pesticides and solvents. Floods remobilize contaminated sediment. Drought concentrates residues in remaining water. Wildfire smoke is a particulate and combustion-product exposure. Warming and nutrient shifts favor harmful algal blooms and some mycotoxins in stored grain. Vector ranges change, which matters when you later think about zoonoses and about pesticide-use patterns that follow those vectors.
Infrastructure. Lead service lines, poorly maintained chemical storage (Bhopal is the extreme industrial case), wastewater overflows, and corrosion-control failures turn engineering into toxicology. The 2014–2015 Flint, Michigan drinking-water crisis is a compact teaching example: a source switch without adequate corrosion control released lead from pipes into tap water, with the highest risk in young children. The toxicology is old (lead and neurodevelopment); the failure mode is infrastructure plus delayed public communication .
Food scarcity. When diets collapse, people eat fish from contaminated water, salvage moldy grain ( aflatoxin , fumonisins), or lose micronutrients that modify toxicity (calcium and iron status change lead absorption). Scarcity is both an exposure amplifier and a susceptibility amplifier.
Infectious disease. Immunotoxic chemicals, wildlife die-offs, and habitat crowding can raise zoonotic contact, as Section 18.1 noted at the ecosystem-service layer. Harmful algal toxins and waterborne pathogens also rise when treatment plants are flooded or overloaded. The candidate's job is to name the toxicological interaction (immunosuppression, food-web change, treatment-plant failure), not to practice clinical infectious-disease boards.
Exposure reconstruction for epidemiologic dose-response (IV.4)
ABT IV.4 is explicit: investigate health outcomes in exposed groups using measured or modeled exposures , and use exposure reconstructions for dose-response evaluation in the context of epidemiological findings. A case-control odds ratio attached to "lived near the plant: yes/no" is not yet a dose-response.
Reconstruction answers "how much, of what, by which route, over which period?" Tools include:
Approach What you actually have Strength Typical bias
Personal or area measurements Air, water, wipe, or duplicate-diet data from the period of interest Best when contemporaneous Missing historical period; wrong matrix
Biomarkers Blood, urine, hair, or other residues Integrates routes; can document uptake Half-life vs latency mismatch; outside contamination of hair
Job-exposure matrices and work histories Assigned intensity × duration Useful for occupational cohorts Mixed jobs; recall of tasks
Environmental fate and dispersion models Release rates + meteorology or hydrology Can fill years with no samples Wrong source term; unvalidated model
Physiologically based pharmacokinetic (PBPK) models Translate external concentration into tissue dose Supports route-to-route and lifestage scaling Parameter uncertainty
Dose-response in observational data still has to respect latency (mesothelioma vs last year's blood level), healthy-worker selection, recall bias, and exposure-measurement error. Classical error often flattens slopes; Berkson-type group assignments behave differently. You are not being asked to derive the full error algebra. You are being asked not to treat a biomarker collected after disease onset as proof of the etiologic dose, and not to skip reconstruction because an association is statistically significant.
Community investigations (ATSDR-style exposure evaluations, state health assessments) should state whether the metric is external concentration , biomarker , or modeled intake , and whether it can be compared with a health-based value. NHANES national percentiles, discussed next, are a context for "is this unusual?" They are not automatically a cleanup standard.
NHANES biomonitoring and study design (IV.5)
The U.S. Centers for Disease Control and Prevention (CDC) National Health and Nutrition Examination Survey , run by the National Center for Health Statistics, has been a continuous survey since 1999 , with data released in two-year cycles . Each cycle uses a complex, stratified, multistage sample designed to represent the U.S. civilian population (on the order of 5,000 persons per year ). Interviews, physical exams, and laboratory assays are linked. CDC's Division of Laboratory Sciences measures environmental chemicals in blood, serum, and urine (and, for some analytes, pooled samples). Results feed the National Report on Human Exposure to Environmental Chemicals , which publishes geometric means and percentiles, often stratified by age, sex, and race/ethnicity.
What NHANES can do for a DABT candidate:
Show temporal trends in population exposure (for example, the long decline in blood lead after leaded gasoline and residential paint controls; declines in some legacy PFAS after production phase-outs; cotinine tracking tobacco-smoke exposure).
Provide a national reference distribution so a clinic or a community mean can be described as high, typical, or low relative to the United States as a whole.
Support research that combines biomarkers with questionnaire data (fish intake vs blood mercury; occupation vs selected metabolites).
What NHANES cannot do, and what the National Exposure Report itself does not claim:
Diagnose an individual or set a clinical toxicity threshold. A 95th percentile is not an RfD.
Provide state- or community-specific causal conclusions. The sample is national, not a local census.
Establish within-person temporality . Each cycle is a new cross-sectional draw, not the same people followed for twenty years.
That last point is IV.5 B: cross-sectional versus longitudinal epidemiology.
Design Structure What it supports What it cannot support alone
Cross-sectional (NHANES cycles; many community spot surveys) Exposure and health measured at one time in each person Prevalence; population distributions; repeated independent samples for trend Incidence; clear "which came first"; individual prognosis
Longitudinal / cohort The same people followed; exposure timed before outcome Temporality; incidence rates; change within person Instant national snapshots; cheap one-time surveys
You can read NHANES as a repeated cross-section to describe national trends. You cannot call it a panel cohort. Community biomonitoring after a spill is also usually cross-sectional. Toxicological interpretation then needs a half-life check: a urine metabolite with a half-life of hours does not reconstruct last year's air concentration, whereas blood lead or some PFAS better reflect longer integrated exposure.
Susceptible subpopulations and biomarkers of susceptibility (IV.6)
ABT IV.6 asks you to identify groups at increased risk in incidents or community/occupational settings , with handbook examples of comorbidities, age, and ethnicity , and biomarkers of susceptibility such as polymorphisms and genetic variants .
Age and life stage. Children inhale and eat more per kilogram, have more hand-to-mouth behavior, and have developing nervous and endocrine systems (lead, MeHg, some pesticides). The fetus is the thalidomide and congenital Minamata lesson: a short window can dominate lifetime risk. Older adults often have reduced glomerular filtration, lower hepatic reserve, polypharmacy, and less physiologic reserve during an inhalation incident (MIC-type pulmonary injury, wildfire smoke).
Comorbidities. Pre-existing asthma, heart failure, chronic kidney disease, and liver disease change both toxicokinetics and toxicodynamics. An inhalation irritant that is a nuisance in a healthy volunteer can decompensate a person with COPD. Reduced renal function slows elimination of metals and some PFAS. Nutritional deficiency (low iron or calcium) increases lead absorption—an intersection of comorbidity, poverty, and infrastructure.
Ethnicity. The handbook lists ethnicity as a susceptibility factor. Use it as a marker , not as a biological essence. Allele frequencies for enzymes such as ALDH2 and G6PD differ across populations; housing stock, occupational distribution, and diet also differ. A DABT-quality answer names the mechanism (enzyme variant, exposure opportunity, access to care), not a stereotype.
Polymorphisms as biomarkers of susceptibility (as distinct from biomarkers of exposure or effect):
- Example Functional consequence Toxicologic relevance
- NAT2 slow acetylator Slower N-acetylation Isoniazid neuropathy; aromatic amine bladder-cancer risk
CYP2D6 poor metabolizer Reduced oxidation of many drugs Higher parent-drug levels; also relevant when a metabolite is the toxic species
- ALDH2*2 Impaired acetaldehyde oxidation Alcohol flush; acetaldehyde-related risk
- GSTM1 null Lost glutathione conjugation capacity Modified risk for some electrophiles
- PON1 variants Altered paraoxonase activity Organophosphate detoxification capacity
- G6PD deficiency Reduced NADPH in erythrocytes Hemolysis after oxidant stress (some drugs, naphthalene)
These markers identify who may need a lower effect level or extra monitoring in an incident. They do not replace exposure reconstruction.
Investigation methods: specimen handling and screen/confirm
Public-health and occupational investigations borrow forensic discipline without turning the DABT into a forensic-board exam. The point is defensibility and the difference between a presumptive result and a confirmed identity.
Specimen handling. Choose the matrix that matches the question: blood or exhaled breath for recent volatile exposure; urine for many metabolites; hair or nails for longer metal windows (with external contamination as a recognized confounder); vitreous humor in postmortem ethanol work when that is the investigation. Label uniquely, record collection time, storage temperature, and chain of custody from collector to laboratory. Freeze or refrigerate according to analyte stability. A perfect assay on an unlabeled tube is not an exposure reconstruction.
Analytical sequence.
Step Typical platform Role Failure mode
Screen Immunoassay (ELISA, related antibody methods) Sensitive, fast, cheap; good for ruling out many negatives Cross-reactivity and false positives; antibody does not equal chemical identity
Confirm / quantify GC-MS or LC-MS/MS Higher specificity; ion ratios, retention time, calibration Wrong method for a thermally labile or poorly ionizing analyte if the platform is forced
Report a screen as presumptive . Report identity and concentration after a validated confirmatory method. That hierarchy is the same whether the case is a workplace methanol incident, a community mercury concern, or a suspected product-tampering event. It is nested here as an investigation method , not as a invitation to memorize forensic courtroom rules.
Risk communication recap for incidents (IV.2 A)
Response plans fail in public when they treat communication as a press release after the science is "done." Elements the handbook groups with response and mitigation:
Risk perception is not a function of the RfD alone. Involuntary, dreaded, inequitable, poorly understood, and child-focused hazards generate more outrage at the same calculated risk (the hazard-plus-outrage framing). MIC clouds, lead in tap water, and thalidomide-type birth-defect stories sit at the high-outrage end.
Say what you know, what you do not know, and what happens next. Over-reassurance that later collapses destroys trust (Flint-style delays; early "safe water" messages).
Actionable advice beats background toxicology: shelter-in-place versus evacuate; do-not-eat fish advisories; when chelation is not indicated; where to get water.
One coordinated scientific voice with public-health authorities, and a channel for community questions (two-way, not broadcast-only).
Mitigation in the same plan: source control, exposure reduction (PPE, engineering, evacuation), and medical management (antidotes when they exist—MIC management is supportive airway care, not a unique chelator).
Put the chapter together the way a DABT item is written. A Minamata-style neurologic cluster plus high fish MeHg is a food-web biomagnification investigation (Section 18.1) plus exposure reconstruction and susceptible fetuses (this section). A first-in-human cytokine storm is not an OECD 203 problem. A high NHANES percentile is a national trend context , not a diagnosis. Independent ExamFinch practice items at /practice/dabt are the place to rehearse those distinctions before exam day.